Taken together, concomitant use of a GC in alleviating side effects in NSCLC patients treated by TKIs should be greatly cautioned and future investigations on signal transduction studies will certainly be needed for better understanding the impact of GCs on inhibition of EGFR TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.